November 15, 2000  presentation

Biomedical Technology -
Where Biology, Medicine and High Tech collide

Moderator

Connie L. Luthy, Ph.D., MBA, CEO and Chief Strategist of The LUTHY Group--Drug Research& Development Consultants

Panelists:

Arthur Bollon, Ph.D, founder, chairman, CEO of Cytoclonal Pharmaceutics;

David Edwards, Ph.D. founder, president, CEO of Hybrigen, Inc.; 

David Camp, Ph.D., president, CEO of International Isotopes Incorporated.

Panel  Overview

As terms such as Biotechnology, Biomedical Technology, Biopharmaceuticals, and Bioinformatics enter the mainstream of business news, investor and scientific excitement over the merging of high tech, biology and medical disciplines is growing. This new paradigm provides the backdrop for the November MIT Forum, which features three companies poised at the leading edge of this new revolution. Chief executive officers (CEOs) of Texas-based Cytoclonal Pharmaceutics Inc., Hybrigen, and International Isotopes Inc., will present the visions of their companies as they lead the way into the fast growing biomedical business sector.

"We are proud to be partnering with the Dallas Forum for BioMedical Technology to bring three such leading companies before the DFW business community," said Neil Kaden, MIT Forum Chairman. "Our moderator, Dr. Connie L. Luthy, works at the national and international levels and has done much to develop a sense of community in the local biomedical industries. I believe they will have an exciting story to tell the entrepreneurs and investors who attend our forums. Our Future Technologies Series focuses on where leading industries are heading. I expect that this one, like our previous program on nanotechnology, will be talked about for some time"

Cytoclonal Pharmaceutics Inc. (CPI), http://www.cytoclonal.com, is a biopharmaceutical company that specializes in developing therapeutic and diagnostic products to treat and prevent cancer and infectious diseases. The company was founded in 1991 and completed an initial public offering (IPO) raising $11.5 million in 1995. The company occupies 22,500 square feet of office and laboratory space. CPI’s lead programs include the improved production of paclitaxel (active ingredient in Taxol) using fermentation and genetic engineering. This program alone is potentially worth up to $50 million or more in royalties from Bristol-Myers Squibb.

Hybrigen, Inc., www.hybrigen.com, was founded in late 1998 after its founder, Dr. Edwards, completed his Ph.D. in Genetics and Development at UTSouthwestern. His eight years of experience using specialized in vivo proteomics test systems and experience as Team Leader of a high-throughput functional genomics screening group were instrumental in developing his vision for the privately held biotechnology company. At Hybrigen invention of cutting-edge platform technologies are accelerating the in-house development and out-licensing of "Bioinformatics Templates" required by pharmaceutical, biotechnology and agribusiness customers to accelerate their own high-value product development programs. Hybrigen’s objective is to become a leader in the explosively growing proteomics sector of business-to-business biotech commerce within the next 3 years. Dr. Edwards is currently completing medical training at UTSW.

International Isotopes Incorporated (I3), http://www.intiso.com, was founded in 1995. I3 is a world leader in commercial, environmentally safe production of high-quality radioisotopes, pharmaceutical grade radioisotopes, and state-of-the-art diagnostic/therapeutic products for medicine. I3 acquired the 70 MeV Linear Accelerator from the now defunct U.S. Superconducting Super Collider (SSC) project and has been commended by the Texas State Legislature for utilization of the SSC assets in the medical field. I3 successfully completed an IPO in 1997.